Positive Topline Data With Nana-val in EBV+ PTCL
Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.
Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.
This cohort study examines the association between pre–allogeneic hematopoietic cell transplant FLT3 internal tandem duplication measurable residual disease level with relapse and death posttransplant in…
Monotherapy with the oral KRAS G12C inhibitor glecirasib demonstrated efficacy in previously treated patients with KRAS G12C–mutated NSCLC, according to data presented during the ASCO…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.
A 51-year-old man with a history of anaphylactic reaction to hornet venom presented with abdominal pain, melena, and bowel habit changes. No skin lesions or…
Leukemia – Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Researchers analyzed the surgical stress response and tissue trauma in patients with NSCLC after robot-assisted and video-assisted procedures using leukocyte count as a surrogate measure.
How long does it take for chemotherapy to start shrinking a tumor? Head and neck specialist and thoracic medical oncologist Janet Tu, M.D., weighs in.
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Hundreds of cancer patients in northwestern Arkansas have access to free transportation to treatment centers thanks to Hope Cancer Resources.